SNIPR Biome reports positive findings for first-in-human, CRISPR-based microbial gene therapy
James Spargo | May 31, 2023 | News story | Research and Development | Infections and infestations, SNIPR Biome, clinical trial, crispr, gene therapy
Danish CRISPR-based microbial gene therapy company SNIPR Biome have announced positive interim data from its phase 1 clinical trial with SNIPR001.
SNIPR001 is a CRISPR-armed phage therapeutic which targets and removes E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract. It is initially being looked at for patients with haematological malignancies who are undergoing haematopoietic stem cell transplants and are vulnerable to blood infections caused by the translocation of E. coli from the gut.
The study tested SNIPR001 in three levels of doses in 36 healthy people, with an aim to study the safety profile, SNIPR001 recovery and pharmacodynamics of the drug. The trial showed that oral dosing over seven days was well-tolerated and that SNIPR001 numerically lowered gut E. coli levels. SNIPR001 could also be recovered in faeces from treated individuals in a dose-dependent manner.
Dr Christian Grøndahl, CEO and co-founder of SNIPR Biome, commented: “We are thrilled with these positive interim results from our phase 1 clinical trial of SNIPR001, which provide clinical validation for this innovative treatment. With the combined killing effects of bacteriophages and CRISPR-Cas technology, SNIPR001 has demonstrated the ability to target and eliminate antibiotic-resistant E. coli strains in the gut, providing a safe alternative to traditional treatments that do not work against antibiotic-resistant strains, while sparing the rest of the gut microbiome. This is a significant milestone in our mission to develop ground-breaking solutions in the fight against antimicrobial resistance, and we look forward to advancing SNIPR001 through further clinical studies to learn more and ultimately, we hope, to improve patient outcomes.”
James Spargo
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
ProteoNic Biosciences launches platform to enhance cell line productivity
ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
